Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: Lessons from recently conducted randomized clinical trials

Current Opinion in Investigational Drugs

Volumn 5, Issue 3, 2004, Pages 313-319

  Boersma, Eric ^a   Westerhout, Cynthia M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Abciximab; Acute coronary syndromes; Eptifibatide; Glycoprotein protein IIb IIIa inhibitors; Lamifiban; Randomized clinical trial(s); Tirofiban

Indexed keywords

ABCIXIMAB; ACETIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; LAMIFIBAN; MONOCLONAL ANTIBODY; PEPTIDE; TIROFIBAN; TYROSINE;

ACUTE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACETATES; ACUTE DISEASE; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; TYROSINE;

EID: 3042673395     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Hamm CW, Bertrand M, Braunwald E: Acute coronary syndrome without ST elevation: Implementation of new guidelines. Lancet (2001) 358(9292):1533-1538.
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet (1994) 343(8893):311-322.
3. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet (2003) 361(9351):13-20.
4. The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet (1997) 349(9063):1429-1435.
5. The RESTORE Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation (1997) 96(5):1445-1453.
6. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med (1997) 336(24):1689-1696.
7. The EPILOG investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet (1997) 352(9122):87-92.
8. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R et al: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation (1996) 94(5):899-905.
9. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM et al: Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation (1996) 94(9):2083-2089.
10. The PRISM Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med (1998) 338(21):1498-1505.
11. The PRISM-PLUS Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med (1998) 338(21):1488-1497.
12. The PARAGON Investigators: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation (1998) 97:2386-2395.
13. The PARAGON-B investigators: Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation (2002) 105(3):316-321.
14. The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med (1998) 339(7):436-443.
15. The GUSTO-IV ACS Investigators: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet (2001) 357(9272):1915-1924.
16. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation (1998) 98(25):2829-2835.
17. Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP, Ferguson JJ 3rd, Willerson JT, Weisman HF, Topol EJ: Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol (2001) 37(8):2059-2065.
18. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J et al: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet (2002) 359(9302):189-198.